Skip to main content
. 2022 Aug 24;14(17):4103. doi: 10.3390/cancers14174103

Table 9.

Immunotherapy and KRAS inhibition, ongoing studies.

Title Status Condition Intervention NCT Number
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients WhoProgressed on First-Line Treatment Recruiting
  • -

    NSCLC

  • -

    AC

  • -

    Stage IV
  • -

    Rigosertib

  • -

    Nivolumab

 NCT04263090
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and efficacy of Sotorasib in subjects with solid tumors with a specific KRAS mutation (codeBreak 100) Recruiting
  • -

    KRAS p.G12C mut

  • -

    Advanced Solid tumor
  • -

    Sotorasib

  • -

    Anti PD-1/L1

  • -

    Midazolam

 NCT03600883
Trametinib and Pembrolizumab in Treating Patients With recurrent NSCLC that is metastatic, unresectable or locally advanced. Active, not recruiting
  • -

    Metastatic NSCLC

  • -

    Stage IIIA-C lung cancer AJCC v8

  • -

    Stage IVA-B lung cancer AJCC v8

  • -

    Unresectable NSCLC
  • -

    Pembrolizumab

  • -

    Trametinib

  • -

    Pharmacokinetic study

 NCT03225664
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7. Recruiting
  • -

    Advanced NSCLC

  • -

    Metastatic NSCLC
  • -

    MRTX849 Monotherapy

  • -

    MRTX849 in Combination with Pembrolizumab

 NCT04613596
Pembrolizumab and Trametinib in Treating Patients With stage IV NSCLC and KRAS gene mutaitons. Active, not recruiting
  • -

    KRAS Gene Mutation

  • -

    Metastatic or recurrent NSCLC

  • -

    Stage IV NSCLC AJCC v7
  • -

    Pembrolizumab

  • -

    Trametinib

 NCT03299088
PDR001 in Patients With Non-small Cell Lung Cancer harboring KRAS/NRAS mutation or no actionable genetic abnormalities. Recruiting
  • -

    Cancer

  • -

    Metastatic Lung Cancer.
  • -

    PDR001

 NCT03693326
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Recruiting
  • -

    NSCLC

  • -

    CRC

  • -

    Advanced Solid Tumors
  • -

    GDC-6036

  • -

    Atezolizumab

  • -

    Cetuximab

  • -

    Bevacizumab

  • -

    Erlotinib

  • -

    GDC-1971

  • -

    Inavolisib

 NCT04449874
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Recruiting
  • -

    Advanced Cancer

  • -

    Metastatic Cancer

  • -

    Malignant Neoplastic Disease
  • -

    MRTX849

  • -

    Pembrolizumab

  • -

    Cetuximab

  • -

    Afatinib

 NCT03785249
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 Recruiting
  • -

    Advanced Cancer

  • -

    Metastatic Cancer

  • -

    Malignant Neoplastic Disease
  • -

    MRTX849

  • -

    Pembrolizumab

  • -

    Cetuximab

  • -

    Afatinib

 NCT03785249
A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation Recruiting
  • -

    NSCLC

  • -

    Solid Tumor
  • -

    BBP-398 with Nivolumab

 NCT05375084
Study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12 C mutation Recruiting
  • -

    KRAS G12C Mutant Solid Tumors

  • -

    NSCLC

  • -

    CRC
  • -

    JDQ443

  • -

    TNO155

  • -

    Tislelizumab

 NCT04699188
A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001) Recruting
  • -

    Advanced Solid Tumors
  • -

    MK-1084

  • -

    Pembrolizumab

 NCT05067283

AC: AdenoCarcinoma; CRC: ColoRectal Cancer; NSCLC: Non-Small Cell Lung Cancer.